These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37311511)

  • 21. Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials.
    Tyagarajan S; Spencer T; Smith J
    Mol Ther Methods Clin Dev; 2020 Mar; 16():136-144. PubMed ID: 31988978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
    Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
    Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
    Stefanski HE; Eaton A; Baggott C; Rossoff J; Verneris MR; Prabhu S; Pacenta HL; Phillips CL; Talano JA; Moskop A; Margossian SP; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski MC; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
    Blood Adv; 2023 Feb; 7(4):541-548. PubMed ID: 35938863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
    Halford Z; Anderson MK; Bennett LL; Moody J
    Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
    Cope S; Ayers D; Zhang J; Batt K; Jansen JP
    BMC Med Res Methodol; 2019 Sep; 19(1):182. PubMed ID: 31477025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Collection efficiency and safety of large-volume leukapheresis for the manufacturing of tisagenlecleucel.
    Kitamura W; Urata T; Fujii K; Fukumi T; Ikeuchi K; Seike K; Fujiwara H; Asada N; Ennishi D; Matsuoka KI; Otsuka F; Maeda Y; Fujii N
    Transfusion; 2024 Apr; 64(4):674-684. PubMed ID: 38419458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
    Wada F; Jo T; Arai Y; Kitawaki T; Mizumoto C; Kanda J; Nishikori M; Yamashita K; Nagao M; Takaori-Kondo A
    Sci Rep; 2022 Nov; 12(1):18696. PubMed ID: 36333521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
    Thomas X; Paubelle E
    Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
    Moskop A; Pommert L; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston ML; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Guest EM; Breese EH; Schultz LM
    Blood Adv; 2022 Jul; 6(14):4251-4255. PubMed ID: 35580324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
    N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
    Pacenta HL; Laetsch TW; John S
    Paediatr Drugs; 2020 Feb; 22(1):1-11. PubMed ID: 31749131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
    Thudium Mueller K; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August KJ; Myers GD; Tam CS; Jaeger U; Foley SR; Borchmann P; Schuster SJ; Waller EK; Awasthi R; Potthoff B; Warren A; Waldron ER; McBlane F; Chassot-Agostinho A; Laetsch TW
    Blood Adv; 2021 Dec; 5(23):4980-4991. PubMed ID: 34432863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
    Fabrizio VA; Curran KJ
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101305. PubMed ID: 34625231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
    O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
    Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
    Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
    Andrade AM; Teixeira VR; Pogue R; Figueiredo ACMG; Carvalho JL
    Cytotherapy; 2023 Sep; 25(9):930-938. PubMed ID: 37341664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.